Professional development Vacancies

Regarding amendments to the instructions for medical use of medicinal products containing thalidomide (thalidomide)

05.10.2021 1349 views

Following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of periodic safety update reports (PSURs) for medicinal products containing thalidomide, the Committee for Medicinal Products for Human Use (CHMP) made the following conclusions.

Taking into account the available data obtained from the cumulative review and the potential class effect regarding the development of hypothyroidism, the PRAC considers that the addition concerning monitoring of thyroid function is justified, in addition to the information already provided on this risk in the section “Adverse reactions” of the instructions for medical use.

PRAC concluded that appropriate amendments should be made to the instructions for medical use of medicinal products containing thalidomide.

CHMP agrees with the scientific conclusions drawn by PRAC.

Based on the scientific conclusions, the CHMP is of the opinion that the benefit-risk balance of medicinal products containing thalidomide remains unchanged, taking into account the proposed changes to the instructions for medical use.

CHMP recommends that registration certificate holders amend the instructions for medical use.

Перелік лікарських засобів, що містять талідомід (thalidomide) і дозволені до медичного застосування в Україні (за даними Державного реєстру лікарських засобів станом на 28.09.2021)

To analyze the published information, the applicant must use the original text available at the linkhttps://www.ema.europa.eu/en/documents/scientific-conclusion/thalidomide-celgene-h-c-psusa-00002919-202010-epar-scientific-conclusions-grounds-variation-terms_en.pdf